China approves Eli Lilly's diabetes drug tirzepatide, increasing competition with Novo Nordisk.
China has approved Eli Lilly's diabetes drug tirzepatide, which sets up increased competition with Novo Nordisk in the Asian market. Tirzepatide, available as Mounjaro for diabetes and Zepbound for weight loss, will now be used in China to treat adults with type 2 diabetes. The global weight-loss drug market, driven by GLP-1 agonists, is expected to reach $100 billion by the end of the decade.
May 21, 2024
7 Articles